Introduction
Periodontal diseases appear to be caused by microorganisms growing in dental plaque and in gingival and subgingival periodontal niches. 1, 2 Traditional therapies for these diseases involved the elimination of subgingival microbial complexes by mechanical debridement such as repeated scaling and surgical procedures. Due to the infective nature of periodontal diseases and with the recognition that the periodontal diseases may be caused by specific etiological agents, interest has grown in use of antimicrobial drugs for elimination of such agents. Local administration of antimicrobial drugs directly into the periodontal pocket has been suggested as a means of bypassing systemic complications and targeting localized areas of periodontal destruction. 3, 4 Minocycline, (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10, 12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide, has been suggested as one of the most effective drugs against periodontal pathogens. 5 It is among the most widely used antibiotics for local delivery owing to its high penetration characteristics throughout most tissues of the mouth such as dentine, enamel of unerupted teeth and the gingiva. Minocycline has been incorporated into a variety of delivery systems for insertion into periodontal pockets. 6, 7 An increased interest in the clinical use of minocycline as an adjunct to periodontal therapy has created a need to determine antibiotic concentrations in biological fluids. This work has been undertaken to study the delivery rate of minocycline from locally administered nano-particulate systems. To optimize dosage schedules and delivery rate of minocycline from these novel delivery systems for periodontal disease therapy, it is useful to relate the drug concentration at the vicinity of infection (in saliva and gingival fluid) and in systemic circulation (plasma). With this objective, the first step is to validate a sensitive method to quantify the drug in biological fluids. The major obstacle to determining minocycline in biological fluids has been the presence of four different dissociation constants in the pH range 1 -12. The compound possesses pKa values of 5 and 9.5 for the two amine functions and 2.8 and 7.8 for the hydroxyl groups, making it unfavorable for chromatography.
A liquid chromatography tandem mass spectrometry (LC-MS) assay was developed by Araujo et al. for the determination of minocycline in human plasma. 8 The method was successfully employed in a bioequivalence study, however, LC-MS methods are expensive, time consuming and complex. Also, several highperformance liquid chromatographic (HPLC) methods have been developed to quantify minocycline in rat plasma and brain, 9 guinea pig tissue and serum, 10 human plasma, 11,12 parotid saliva, 11 serum and urine. 13 Most of the published methods either employ large sample volumes or have long extraction procedures such as solid phase extraction 10, 11 or liquid-liquid reextractions. 13 In a method developed by Orti et al., the limit of quantification (100 ng mL -1 ) was high. 11 The most sensitive method has a limit of quantification of 30 ng mL -1 , but has low recovery rates. 12 The extraction of minocycline is difficult because it undergoes acid-, basic-and photo-degradation, resulting in low recovery rates. Earlier, we have reported the validated, stability-indicating HPTLC method for determination of minocycline in pharmaceutical dosage forms. 14 In order to determine antibiotic levels, we developed an 58 ANALYTICAL SCIENCES JANUARY 2009, VOL. 25 HPTLC method that was capable of evaluating minocycline concentrations in human plasma, saliva and gingival fluid. The procedure is fast and simple and involved a single step extraction with methanol. The method was validated with respect to accuracy, precision, robustness, selectivity, limit of quantification and limit of detection. This paper also details the stability and degradation kinetics of minocycline in the studied biomatrices. Moreover, the proposed HPTLC method was suitable for pharmacokinetic study of minocycline.
Experimental

Reagents
Minocycline was received as a gift sample from Ranbaxy Laboratories Ltd. (Gurgaon, Haryana, India) and certified to contain 99.62% (w/w) on a dried basis. All other chemicals and reagents used were of analytical grade and were purchased from Merck Ltd. (Worli, Mumbai, India). For validation of the method, human plasma, saliva and gingival fluid samples were collected from healthy human volunteers (Majeedia Hospital, Delhi, India). Gingival fluid samples were collected by means of glass capillary tubes. 15 All samples were frozen at -20˚C until analysis.
Chromatography
The samples were spotted in the form of bands of width 5 mm with Camag 100 mL syringe using a Linomat V (Camag, Muttenz, Switzerland) sample applicator. The precoated silica gel aluminium plates 60F-254 (20 cm ¥ 10 cm ¥ 200 mm, E. Merck, Germany) were used after spraying with a 10% (w/v) solution of EDTA (ethylene diaminetetraacetic acid), the pH of which was adjusted to 9.0 with a 10% (w/v) solution of sodium hydroxide. The application rate, slit dimensions, scanning speed and development conditions were the same as those reported previously.
14 In brief, the mobile phase consisted of methanolacetonitrile-isopropyl alcohol (IPA)-water (5:4:0.5:0.5). Linear ascending development was carried out in 20 cm ¥ 10 cm twin through-glass chambers (Camag, Switzerland). The optimized chamber saturation time for mobile phase was 30 min at room temperature (25˚C ± 2) at a relative humidity of 60 ± 5%. Densitometric scanning was performed on a Camag TLC scanner III in absorbance mode at 345 nm and operated by winCATS software (Version 1.2.0). The source of radiation utilized was deuterium lamp emitting a continuous UV spectrum in the range of 190 -400 nm. Evaluation was done using linear regression analysis via peak areas as a function of theoretical concentrations applied to each standard curve (formula: y = a + bx; where x = concentration (mg mL -1 ) and y = peak area). The resulting slopes and intercepts were used to obtain concentration values for the day's quality control samples.
Calibration standards and quality control (QC) samples
Calibration standards and quality control samples of plasma and saliva. A stock solution of minocycline was prepared by dissolving 150 mg of minocycline in 10 mL of methanol. Working solutions ranging from 1 -12 mg mL -1 were prepared by properly diluting the stock solution with methanol. Ten microliters of each working solution of minocycline were used to spike plasma and saliva samples (1 mL) in order to obtain calibration standards ranging from 10 -120 mg mL -1 . QC samples were prepared at concentrations of 20, 60 and 100 mg mL -1 . Each level was divided into aliquots of 1.0 mL and immediately frozen at -20˚C. Calibration standards and quality control samples of gingival fluid. The typical gingival fluid volumes collected were 0.1 -1 mL, calibration standards in gingival fluid were therefore prepared by diluting the stock solution with gingival fluid to obtain the highest calibration sample and continuing successive dilutions with blank gingival fluid as needed. A calibration row of eight levels including a blank was thus obtained, extending from 1 -12 mg mL -1 . QC samples were prepared at concentrations of 2, 6 and 10 mg mL -1 . Each level was divided into aliquots of 1.0 mL and immediately frozen at -20˚C.
Sample preparation
Prior to analysis, plasma, saliva and gingival fluid samples were thawed at room temperature for about 10 min. One milliliter of plasma and saliva calibration standards and QC samples and 1.0 mL of gingival fluid calibration standards and QC samples were transferred into Eppendorf tubes and mixed with 1.0 mL of methanol. After vortex mixing for 1 min, the samples were centrifuged (5 min, > 2000g). The supernatant was transferred to glass microvials and the solvent was evaporated at 37˚C under nitrogen stream.
The plasma and saliva samples were reconstituted with 100 mL of methanol, whereas gingival fluid samples were reconstituted with 10 mL of methanol. One microliter of each sample was spotted on the TLC plate to obtain the final calibration range of 100 -1200 ng spot -1 . QC samples at final concentration of 200, 600 and 1000 ng spot -1 were obtained after spotting. Each concentration was spotted six times on the TLC plate. The data of peak areas plotted against corresponding concentration were treated by linear-square regression analysis.
Method validation
Specificity. The specificity of the method was investigated by screening three different batches of blank human plasma, saliva and gingival fluid samples. All the samples were cleaned up as described in the sample preparation section. The Rf values of endogenous compounds in the matrix were compared with those of minocycline. Precision and accuracy. The precision and accuracy of the method were evaluated by performing replicate analyses of QC samples (200, 600 and 1000 ng spot -1 ) in plasma, saliva and gingival fluid against a calibration curve. Intra-day repeatability was determined by treating spiked samples in six replicates on the same day. Inter-day repeatability was studied by comparing the results of assays performed on different days on the same spiked samples, also in six replicates for each kind of sample. The reproducibility of the method was checked by determining precision on a different instrument, analysis being performed by another person in a different laboratory. The precision was expressed in terms of intra-day and inter-day coefficient of variation (CV, %), whereas accuracy was expressed as percent recovery (mean measured concentration/nominal concentration ¥ 100). Robustness. The robustness of the method was determined to assess the effect of small but deliberate variation of the chromatographic conditions on the determination of minocycline. Robustness studies were done in triplicate for plasma, saliva and gingival fluid samples at a concentration level of 600 ng spot -1 . Methanol-acetonitrile-IPA-water (v/v/v/v) mixtures in varying ratios (5.0 ± 0.5; 4.0 ± 0.4; 0.5 ± 0.05; 0.5 ± 0.05) were tried and chromatograms were run. The amounts of mobile phase and durations of saturation were varied at 20 ± 2 mL (18, 20 and 22 mL) and 30 ± 10 min (20, 30 and 40 min), respectively. Concentrations and pH values of the EDTA solution were varied at 10 ± 1% (9, 10 and 11%) and pH 9 ± 1 (pH 8, 9 and 10). The time from spotting to chromatography and from chromatography to scanning was varied from 0, 10 and 20 min. The effects on the results were expressed as standard deviations. Limit of detection and limit of quantitation. In order to estimate the limit of detection (LOD) and limit of quantitation (LOQ), we spotted blank plasma, saliva and gingival fluid samples six times following the same method as mentioned previously, and we determined the standard deviations (s) of the magnitude of analytical response. The LOD was expressed as 3.3s/slope of the calibration curve of the minocycline, whereas LOQ was expressed as 10s/slope of the calibration curve of the minocycline. Recovery studies. The extraction efficiency (recovery) was determined in triplicate at 200, 600 and 1000 ng spot -1 for minocycline in all the three matrices. The peak areas obtained after extraction were compared with peak areas resulting from standard solutions at the same concentrations.
Stability study QC samples. For the determination of stability, QC samples at three concentrations were used. After spiking in plasma, saliva and gingival fluid, aliquots were stored at 4 and 20˚C. The stability was assessed after 0.5, 1, 2, 4 and 8 h. The stability of the drug in frozen samples (-20˚C) was determined by periodic analysis over a period of 2 months. Prior to analysis, samples were brought to room temperature and extraction was performed. Degradation rate constant (Kobs), half-life (t1/2) and shelf life (t90) (i.e. time where 90% of original concentration of the drug is left) of the drug in plasma, saliva and gingival fluid were also obtained at 4 and 20˚C. Freeze-thaw stability. For freeze-thaw stability, nine aliquots of each QC sample (in each matrix) were stored at -20˚C for 24 h; they were then left to completely thaw at room temperature. Three aliquots of each QC sample (in each matrix) were analyzed after extraction. The rest of the aliquots were returned to -20˚C for another 24 h. The cycle was repeated three times. Stock solution. The stability of the drug in methanol (stock solution) was assessed at 4 and 20˚C. Run time stability at room temperature of processed samples after extraction was determined for QC samples. To test the stability, we analyzed the samples immediately after preparation (control) and after a stipulated time period.
Pharmacokinetic study
In order to verify the applicability of this method, the pharmacokinetic study with marketed minocycline tablet preparation was conducted in 3 healthy volunteers after a single oral dose of 100 mg. The blood, saliva and gingival fluid samples were obtained at 1.0, 2.0, 4.0, 8.0, 12.0 and 24.0 h after dosing. The blood samples were collected in heparinized tubes and plasma was collected and separated after being centrifuged at 1000g for 20 min. The saliva and gingival fluid samples were collected as described above in the experimental section. All the samples were frozen at -20˚C until analysis.
Results
Calibration curves
The linear regression data for the calibration curves in plasma, saliva and gingival fluid are shown in Table 1 . Under the described conditions, and in all the three matrices, minocycline was well resolved at Rf = 0.32. The peak area of minocycline varied linearly with concentration over the range used. The peak area vs. concentration fitted well to a straight line, with the following equations for the calibration curves: y = (9.873 ± 0.042)x + (1832.48 ± 13.35); y = (8.943 ± 0.016)x + (1504.92 ± 8.43) and y = (9.271 ± 0.025)x + (1632.56 ± 12.92) in plasma, saliva and gingival fluid, respectively.
The correlation coefficients (r 2 ) for calibration curves were equal to or better than 0.9958. No significant difference was observed in the slopes of standard curves (ANOVA, P > 0.05).
Specificity
Representative chromatograms of drug free plasma, saliva and gingival fluid are shown in Figs. 1(a), 2(a) and 3(a) , respectively. Plasma, saliva and gingival fluid spiked at concentration of 600 ng/spot are shown in Figs. 1(b), 2(b) and 3(b) , respectively. As shown in Figs. 1, 2 and 3 , the Rf (0.32) where minocycline eluted was free of interferences in all of the drug free human plasma, saliva and gingival fluid samples. Table 2 summarizes the intra-and inter-day precision and accuracy of the assay determined for QC samples at concentrations of 200, 600 and 1000 ng spot -1 . The intra-day precision was equal to or less than 3.49, 3.59 and 4.19% in plasma, saliva and gingival fluid, respectively. The values for inter-day precision were equal to or less than 4.14, 3.95 and 4.61% in plasma, saliva and gingival fluid, respectively. The intra-and inter-day accuracy, calculated as percent recovery, ranged from 95.08 to 100.6% for the matrices studied. Reproducibility was checked by measuring the precision of the method in another laboratory on a different instrument with analysis performed by another person. Both intra-day and interday precision were determined. The low values of CV (< 4.61%), with no significant differences between values for intra-day and inter-day precision, indicate that the method is reproducible. Table 3 summarizes the average values of SD, SE and % RSD of the peak areas for each parameter at a concentration level of 600 ng spot -1 in plasma, saliva and gingival fluid. The low values of % RSD (£0.783) and SE (£1.775) obtained after introducing small deliberate changes in the developed HPTLC method indicated the robustness of the method.
Precision and accuracy
Robustness
LOD and LOQ
The LOD expressed as 3.3s/slope of the calibration curve of the minocycline and LOQ expressed as 10s/slope of the calibration curve of the minocycline were found to be 5.1 and 15.4 ng spot -1 , respectively, which indicates the adequate sensitivity of the method.
Extraction recovery
In plasma, the mean recovery (n = 6) averaged 95.8 ± 4.5% for minocycline. In saliva (n = 6) and gingival fluid (n = 6) the recoveries were 99.4 ± 1.7% and 98.1 ± 2.9%, respectively. The extraction efficiency is not statistically different over the range of concentration studied.
Stability
The stability of minocycline was investigated in human plasma, saliva and gingival fluid samples. Each experiment was repeated three times and the mean concentration of minocycline was calculated. A monoexponential decline in drug concentration was observed at both 20 and 4˚C, in all the three biomatrices studied. After storage at 20˚C for 8 h the drug degradation was substantial and the percentage recovery of minocycline decreases to 38.3 ± 2.96, 60.5 ± 3.94 and 57.2 ± 7.24% of the initial concentrations in plasma, saliva and gingival fluid, respectively. In contrast, higher recovery of minocycline in plasma (54.5 ± 6.54%), saliva (70.4 ± 0.89%) and gingival fluid (69.9 ± 1.56%) was obtained after storage at 4˚C for 8 h. The degradation rate constant (Kobs) of minocycline in plasma, saliva and gingival fluid were 0.11, 0.06 and 0.076 h -1 , respectively at 20˚C, indicating that the drug was least stable in plasma (Table 4) . Moreover, half-life (t1/2) and shelf life (t90) of drug in plasma, saliva and gingival fluid were obtained from the slope of the straight lines at both temperatures (Table 4 ). The corresponding half-life values ranged from 6.3 to 11.5 h at 20˚C and from 9.9 to 16.1 h at 4˚C.
The long term freezer stability (-20˚C) indicated that minocycline was stable in the studied matrices during 2 months. The percent recovery averaged 95.1%. The freeze-thaw data indicate that, as a minimum, two freeze-thaw cycles can be tolerated without losses higher than 10%.
Stock solutions of minocycline were stable for 2 days at 20˚C and for 6 days at 4˚C without measurable degradation. Stability at room temperature of processed samples after extraction was determined. After 12 h no significant losses occurred.
Pharmacokinetic study
The method was used for analysis of plasma, saliva and gingival fluid samples obtained after oral administration of a single minocycline tablet (100 mg). Figure 4 shows the mean concentration-time profiles for minocycline. The maximum plasma concentration (Cp max) was found to be 1059 ± 40 ng mL -1 , which is significantly higher than the maximum saliva concentration (Cs max, 161 ± 16 ng mL -1 ) and the maximum gingival fluid concentration (Cg max, 282 ± 18 ng mL -1 ). The result indicates that higher plasma levels were obtained after oral administration of minocycline, whereas lower drug concentration was obtained at the vicinity of infection, i.e. in saliva and gingival fluid (Fig. 4) . Experimental Cp max values after oral administration were comparable with reported data, 16 indicating that this method is suitable for pharmacokinetic studies.
Discussion
This is the first validated HPTLC method for determination of minocycline in human plasma, saliva and gingival fluid samples. This method has low detection limits, high recovery rate, wide dynamic range with acceptable precision and a short extraction procedure when compared with other methods. [9] [10] [11] [12] [13] Since the sample processing procedure is short and simple, the external standard method was tried. The present method, devoid of internal standard, is robust and %CVs of the minocycline in biological matrices was £4.61%. Under the described conditions, the Rf (0.32) where minocycline eluted, was free of interferences in all of the drugfree human plasma, saliva and gingival fluid tested. The use of TLC plates sprayed with 10% (w/v) solution of disodium EDTA, pH 9.0, allows us to prevent the formation of minocycline-metal complexes and improves peak symmetry. UV spectra measured on the spots showed maximal absorbance at about 345 nm owing to cyclic structures of minocycline.
Densitometric analysis at 345 nm improved the detection sensitivity, specificity and minimizes interferences from biological fluids that may occur at lower wavelengths. The methanol used to elute the plasma samples enables rapid extraction with few impurities and no interfering substances. The present method is also used to study the stability of minocycline in plasma, saliva and gingival fluid. The results indicate that the rapid degradation of drug occurred in the three matrices and that the half-life of the drug ranged from 9.9 to 16.1 h at 4˚C and from 6.3 to 11.5 h at 20˚C. However, there was no significant degradation of the compound following extraction with methanol. We found that stock solutions of minocycline in methanol were stable for 2 days at 20˚C and for 6 days at 4˚C without measurable degradation. The method described is a sensitive and specific assay for minocycline in biomatrices and is suitable for pharmacokinetic studies after therapeutic doses.
Conclusion
In summary, we have developed a robust, reliable, and sensitive method for determination of minocycline in plasma, saliva and gingival fluid. The method could be used to carry out pharmacokinetic studies of the minocycline from novel intraperiodontal delivery systems.
